Granules gets USFDA nod to market generic medication to treat high blood pressure
The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2023 Category: Pharmaceuticals Source Type: news
Blood Pressure Drug for COVID-Induced Lung Injury? Blood Pressure Drug for COVID-Induced Lung Injury?
Despite promising results in preclinical models, angiotensin-receptor blockade with losartan did not reduce lung injury in hospitalized COVID-19 patients in this randomized clinical trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Losartan Does Not Reduce Lung Injury in Hospitalized COVID-19 Patients
WEDNESDAY, March 16, 2022 -- Administration of losartan to hospitalized patients with COVID-19 and acute lung injury is not efficacious for reducing lung injury, according to a study published online March 16 in JAMA Network Open.
Michael A.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 16, 2022 Category: Pharmaceuticals Source Type: news
Common blood pressure drug does not slow down the progression of more advanced Alzheimer ’ s, study finds
New research led by the University of Bristol, has shown the drug losartan, normally used to treat high blood pressure (hypertension), is not effective in slowing down the progression of Alzheimer ’ s disease (AD) in people with mild-to-moderate disease after 12 months of treatment. However, the drug could still be of benefit if prescribed for longer and if given to people with very early disease. The findings are from the phase 2 multi-centre clinical trial known as RADAR ((Reducing pathology in Alzheimer ’ s Disease through Angiotensin taRgeting). (Source: University of Bristol news)
Source: University of Bristol news - November 15, 2021 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Translational Health Sciences; Press Release Source Type: news
Common blood pressure drug does not slow down the progression of more advanced Alzheimer ’ s
New research led by the University of Bristol, has shown the drug losartan, normally used to treat high blood pressure (hypertension), is not effective in slowing down the progression of Alzheimer ’ s disease (AD) in people with mild-to-moderate disease after 12 months of treatment. However, the drug could still be of benefit if prescribed for longer and if given to people with very early disease. The findings are from the phase 2 multi-centre clinical trial known as RADAR ((Reducing pathology in Alzheimer ’ s Disease through Angiotensin taRgeting). (Source: University of Bristol news)
Source: University of Bristol news - November 15, 2021 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Translational Health Sciences; Press Release Source Type: news
Losartan to slow the progression of mild-to-moderate Alzheimer's disease through angiotensin targeting: the RADAR RCT
This study investigated whether taking the antihypertensive drug losartan, in addition to normal care, would slow the progression of Alzheimer ' s disease when compared with a placebo. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 3, 2021 Category: Consumer Health News Source Type: news
Researchers discover how cancer cells that spread to lymph nodes avoid immune destruction
(Massachusetts General Hospital) New research provides insights on why cancer cells that spread to lymph nodes can often avoid being eliminated by immune cells. The blood pressure drug losartan may help overcome this immune evasion. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: news
Antihypertension drug may help patients with noncancerous brain tumors affecting hearing
(Massachusetts General Hospital) New research led by investigators at Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear indicates that the blood pressure drug losartan may benefit patients with neurofibromatosis type 2. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news
Researchers find losartan is not effective in reducing hospitalization from mild COVID-19
(University of Minnesota Medical School) University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 18, 2021 Category: Infectious Diseases Source Type: news
Class 2 Medicines Recall: Bristol Laboratories Limited, Brown & Burk UK Ltd, Teva UK Ltd, Irbesartan-containing and Losartan-containing products
Specific batches of products supplied by Bristol Laboratories Limited, Brown& Burk UK Limited and Teva UK Limited are being recalled due to presence of a mutagenic impurity.
Further information (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - June 17, 2021 Category: Drugs & Pharmacology Source Type: news
Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP and 54 lots of Losartan potassium/ hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient ( (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
